TRAIN-HEART Network

The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.


People

TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.


Research Programme

The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.


Contact

If you have any questions you can fill in the form or mail us directly: info@train-heart.eu.





News

Checkout the new and impressive paper "Nano-miR-133a Replacement Therapy Blunts Pressure Overload–Induced Heart Failure"


You can access the article HERE


Modica J, Di Mauro V, Barandalla-Sobrados M, Chavez SEP, Carullo P, Nemska S, Anselmo A, Condorelli G, Iafisco M, Miragoli M, Catalucci D. Nano-miR-133a Replacement Therapy Blunts Pressure Overload-Induced Heart Failure. Circulation. 2021 Dec 14;144(24):1973-1976. doi: 10.1161/CIRCULATIONAHA.121.055866. Epub 2021 Dec 13. PMID: 34898244.